Quick Answer
CRISPR Therapeutics AG reported Operating Income of -$664.57 million for fiscal year 2025.
CRISPR Therapeutics AG Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$664.57M | -42.4% |
| 2024 | -$466.57M | -109.7% |
| 2023 | -$222.54M | +66.9% |
| 2022 | -$673.16M | -280.2% |
| 2021 | $373.53M | +205.4% |
| 2020 | -$354.44M | -858.3% |
| 2019 | $46.74M | +129.4% |
| 2018 | -$158.94M | -145.9% |
| 2017 | -$64.65M | +5.1% |
| 2016 | -$68.13M | -164.8% |
| 2015 | -$25.73M | -288.2% |
| 2014 | -$6.63M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$132.06M | -19.9% | +42.4% |
| June 30, 2025 | -$229.32M | -51.6% | -54.5% |
| March 31, 2025 | -$148.42M | -5.6% | -34.8% |
| September 30, 2024 | -$110.13M | +16.8% | +27.2% |
| June 30, 2024 | -$151.26M | -58.8% | -7.6% |
| March 31, 2024 | -$140.59M | -118.0% | -6.2% |
| September 30, 2023 | -$132.41M | +27.4% | -39.1% |
| June 30, 2023 | -$95.22M | +48.0% | -47.7% |
- CRISPR Therapeutics AG showed a decrease of -42.4% in Operating Income compared to the prior fiscal year.
- Over the 2014–2025 period, CRISPR Therapeutics AG’s operating income has declined by 9928.2% (from -$6.63 million to -$664.57 million).
- The most recent figure is from CRISPR Therapeutics AG’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: